Synthesis, Optimization, and Evaluation of Novel Small Molecules as Antagonists of WDR5-MLL Interaction

被引:52
作者
Bolshan, Yuri [1 ]
Getlik, Matthaeus [2 ]
Kuznetsova, Ekaterina [1 ]
Wasney, Gregory A. [1 ]
Hajian, Taraneh [1 ]
Poda, Gennadiy [2 ]
Nguyen, Kong T. [1 ]
Wu, Hong [1 ]
Dombrovski, Ludmila [1 ]
Dong, Aiping [1 ]
Senisterra, Guillermo [1 ]
Schapira, Matthieu [1 ]
Arrowsmith, Cheryl H. [1 ]
Brown, Peter J. [1 ]
Al-awar, Rima [2 ]
Vedadi, Masoud [1 ]
Smil, David [1 ]
机构
[1] Univ Toronto, Struct Genom Consortium, MaRS Ctr, Toronto, ON M5G 1L7, Canada
[2] Ontario Inst Canc Res, MaRS Ctr, Toronto, ON M5G 0A3, Canada
基金
英国惠康基金;
关键词
WDR5; MLL; SET1 methyltransferase complex; peptide binding site; small molecule antagonists; HISTONE H3; DROSOPHILA-TRITHORAX; ACUTE LEUKEMIAS; CORE COMPLEX; HOX GENES; MLL; METHYLATION; RECOGNITION; METHYLTRANSFERASES; TRANSLOCATIONS;
D O I
10.1021/ml300467n
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The WD40-repeat protein WDRS plays a critical role in maintaining the integrity of MLL complexes and fully activating their methyltransferase function. MLL complexes, the trithorax-like family of SET1 methyltransferases, catalyze trimethylation of lysine 4 on histone 3, and they have been widely implicated in various cancers. Antagonism of WDR5 and MLL subunit interaction by small molecules has recently been presented as a practical way to inhibit activity of the MLL1 complex, and N-(2-(4-methylpiperazin-1-yl)-5-substituted-phenyl) benzamides were reported as potent and selective antagonists of such an interaction. Here, we describe the protein crystal structure guided optimization of prototypic compound 2 (K-dis = 7 mu M), leading to identification of more potent antagonist 47 (K-dis = 0.3 mu M).
引用
收藏
页码:353 / 357
页数:5
相关论文
共 26 条
[1]   Hox genes in hematopoiesis and leukemogenesis [J].
Argiropoulos, B. ;
Humphries, R. K. .
ONCOGENE, 2007, 26 (47) :6766-6776
[2]   Structural and Biochemical Insights into MLL1 Core Complex Assembly [J].
Avdic, Vanja ;
Zhang, Pamela ;
Lanouette, Sylvain ;
Groulx, Adam ;
Tremblay, Veronique ;
Brunzelle, Joseph ;
Couture, Jean-Francois .
STRUCTURE, 2011, 19 (01) :101-108
[3]   Regulation of MLL1 H3K4 methyltransferase activity by its core components [J].
Dou, Yali ;
Milne, Thomas A. ;
Ruthenburg, Alexander J. ;
Lee, Seunghee ;
Lee, Jae Woon ;
Verdine, Gregory L. ;
Allis, C. David ;
Roeder, Robert G. .
NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2006, 13 (08) :713-719
[4]   Open access chemical and clinical probes to support drug discovery [J].
Edwards, Aled M. ;
Bountra, Chas ;
Kerr, David J. ;
Willson, Timothy M. .
NATURE CHEMICAL BIOLOGY, 2009, 5 (07) :436-440
[5]   WRAD: enabler of the SET1-family of H3K4 methyltransferases [J].
Ernst, Patricia ;
Vakoc, Christopher R. .
BRIEFINGS IN FUNCTIONAL GENOMICS, 2012, 11 (03) :217-226
[6]   THE T(4-11) CHROMOSOME-TRANSLOCATION OF HUMAN ACUTE LEUKEMIAS FUSES THE ALL-1 GENE, RELATED TO DROSOPHILA-TRITHORAX, TO THE AF-4 GENE [J].
GU, Y ;
NAKAMURA, T ;
ALDER, H ;
PRASAD, R ;
CANAANI, O ;
CIMINO, G ;
CROCE, CM ;
CANAANI, E .
CELL, 1992, 71 (04) :701-708
[7]   High-Affinity, Small-Molecule Peptidomimetic Inhibitors of MLL1/WDR5 Protein-Protein Interaction [J].
Karatas, Hacer ;
Townsend, Elizabeth C. ;
Cao, Fang ;
Chen, Yong ;
Bernard, Denzil ;
Liu, Liu ;
Lei, Ming ;
Dou, Yali ;
Wang, Shaomeng .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2013, 135 (02) :669-682
[8]   Chromatin modifications and their function [J].
Kouzarides, Tony .
CELL, 2007, 128 (04) :693-705
[9]   MLL translocations, histone modifications and leukaemia stem-cell development [J].
Krivtsov, Andrei V. ;
Armstrong, Scott A. .
NATURE REVIEWS CANCER, 2007, 7 (11) :823-833
[10]   Therapeutic targeting of MLL [J].
Liedtke, Michaela ;
Cleary, Michael L. .
BLOOD, 2009, 113 (24) :6061-6068